RxDoctor Payments Data

James Miller, MD

Internal Medicine · Columbus, GANPI 1598752560

Payments from drug & device makers

$7,951in general payments, 2019–2025

Across 463 payments — averaging $17.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • Novo Nordisk$976
  • Boehringer Ingelheim$893
  • Lilly USA, LLC$887
  • GSK$556
  • Bayer$511
  • plus $3K from 28 others

What the payments were for

  • Food & beverage$7,951100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$7,951 in reported general payments places this provider in the 90th percentile of 3,311 internal medicine providers in Georgia.

See all internal medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$83,063
Medicare patients
234
Services billed
1,129

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin68$98,868
OzempicSemaglutide58$88,670
MounjaroTirzepatide70$86,744
Xeljanz XrTofacitinib Citrate14$85,464
TrulicityDulaglutide46$46,537
EliquisApixaban25$34,346
Trelegy ElliptaFluticasone/Umeclidin/Vilanter32$28,358
FarxigaDapagliflozin Propanediol17$26,864
Tresiba Flextouch U-200Insulin Degludec12$20,849
XareltoRivaroxaban17$20,611
LinzessLinaclotide12$16,357
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr18$8,185
Colesevelam Hcl15$5,815
Testosterone13$5,251
SymbicortBudesonide/Formoterol Fumarate23$5,039

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$887$133,281116 claims
Boehringer IngelheimJardiance$893$98,86868 claims
Novo NordiskOzempic$976$88,67058 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$556$40,03661 claims
PfizerEliquis$319$34,34625 claims
AstraZenecaFarxiga, Symbicort$1,199$31,90340 claims
Johnson & JohnsonXarelto$312$20,61117 claims
AbbVieLinzess$184$16,35712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,311 internal medicine providers in Georgia.

Other internal medicine in Columbus

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →